Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. (DTCFF) is a clinical-stage biopharmaceutical company pioneering next-generation cancer therapies and precision drug delivery systems. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic partnerships, and technological advancements.
Access the latest press releases and news covering Accum™-enabled therapeutics, including radiopharmaceuticals, antibody-drug conjugates (ADCs), and immune-oncology vaccines. Stay informed about regulatory milestones, licensing agreements, and intellectual property developments that underscore the company’s position in the biotech sector.
Key updates include progress in Phase I trials for AccuTOX®, collaborations with research institutions, and patent grants for novel drug delivery methods. All content is curated to provide a comprehensive view of Defence Therapeutics’ scientific and corporate trajectory.
Bookmark this page for streamlined access to verified updates on DTCFF’s innovations in oncology and infectious disease treatment. Regularly updated to reflect the company’s evolving role in advancing targeted therapies.
Defence Therapeutics announced the publication of a peer-reviewed study on AccuTOX, an anti-cancer molecule, in the Journal of Translational Medicine. The study details how AccuTOX synergizes with immune-checkpoint inhibitors to disrupt tumor growth. AccuTOX, derived from the Accum platform, shows enhanced killing potency, versatility, and ease of manufacturing. It induces immunogenic cell death and enhances cancer cell visibility to the immune system. The compound targets multiple cancer cell lines and has shown no apparent toxicity in animal models. Defence is initiating a Phase I trial and has submitted a CTA application to Health Canada.
Defence Therapeutics, a biopharmaceutical firm, announced the issuance and allowance of multiple patents across several Patent Families. The US Patent Office allowed application no. 18/169,440, enhancing the company's vaccine platform technology, Accum®, known for boosting antigen presentation. Recent pre-clinical studies using Defence's ARM-002™ vaccine showed significant antitumor responses, paving the way for Phase I trials.
Another patent in Australia for Defence's ADC platform was granted on February 1, 2024, further protecting Accum® and its variants, and adding to existing patents in the US, Japan, and Israel. Additionally, patents for Defence's vaccine platform technology were granted in Canada and Australia, with a Japanese patent expected soon. These patents cover methods and compositions for enhancing antigen immunogenicity.
CEO Mr. Plouffe highlighted the importance of these patents in Defence's mission to innovate and improve human health. The company is accelerating the examination of remaining applications via the Patent Prosecution Highway (PPH) program.
Defence Therapeutics Inc. announces successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer, showing therapeutic effectiveness when combined with an immune-checkpoint inhibitor. Results reveal potent vaccine efficacy with tumor growth inhibition, positioning the company to target 'hard-to-treat' cancers like pancreatic cancer. The pancreatic cancer market is projected to exceed USD 36 billion by 2036.
FAQ
What is the current stock price of Defence Therapeu (DTCFF)?
What is the market cap of Defence Therapeu (DTCFF)?
